CD274 and carcinoma: Clinical trial NCT03544723 is a Phase II multi-centre study to evaluate adenoviral-mediated p53 delivery in combination with immune checkpoint inhibitors, such as anti-PD-1/anti-PD-L1 in patients with carcinomas approved for anti-PD-1 and anti-PD-L1 therapy.